Nuevas estrategias terapéuticas en la osteoporosis

In the last few years, the therapeutic arsenal available for the treatment of this disease has changed substantially with drugs that have been tested in randomized, double-blind, placebo-controlled clinical trials. These studies have allowed the effect of these drugs on fractures -the most important data for their use- to be studied. Therefore, taking into account these new reports, as well as the percentage 10-year risk of fracture among the population, therapeutic criteria can be established. These criteria are analyzed in the present review.